One in eight women in the US will develop breast cancer in their lifetime.1 Many of these women, however, will ultimately add “survivor” to their diagnosis thanks to today’s treatment options. Breast cancer survival has tripled in the last 60 years2, demonstrating just how far we’ve come in fighting a disease that once spelled death.

The success of existing treatments is largely due to our understanding of the genomic drivers of breast cancer. Genomic profiling has redefined the treatment landscape, allowing us to stratify breast cancer by molecular subtype in order to tailor treatment approaches.3

At this year’s San Antonio Breast Cancer Symposium (SABCS), we are proud to contribute new insights to the fight against breast cancer through comprehensive genomic profiling (CGP). Using our large-scale genomic data sets, we hope to help identify novel therapeutic targets and pave the way for new treatments. Our presentations include data on thousands of breast cancer samples that could identify targetable molecular subtypes and that shed light on the spectrum of mutations that underlie breast cancer.

This is important because, although survival has steadily improved, the fight against breast cancer isn’t over yet. Treatments that have worked for years can suddenly become ineffective as a cancer develops new resistance mutations. To ensure our continued success in this fight, we need to better understand the complexity of the molecular drivers that lead to breast cancer and its resistance mechanisms. We also need to search for and characterize new mutations that may serve as future therapeutic targets.

CGP is giving us a deeper look into how these mutations occur and how they might influence response to treatment. The FoundationOne® CGP assay can probe hundreds of cancer-related genes simultaneously to identify new mutations or uncover novel subsets of mutations that may be targetable by existing therapies.

Our presentations at SABCS this year include: